2,000 reports of this reaction
1.2% of all MEPOLIZUMAB reports
#20 most reported adverse reaction
HOSPITALISATION is the #20 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 2,000 FDA adverse event reports linking MEPOLIZUMAB to HOSPITALISATION. This represents approximately 1.2% of all 173,706 adverse event reports for this drug.
Patients taking MEPOLIZUMAB who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for MEPOLIZUMAB, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for MEPOLIZUMAB:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 2,000 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 1.2% of all adverse event reports for MEPOLIZUMAB, making it a notable side effect.
If you experience hospitalisation while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.